Recursion director trades 40,000 shares in plan sale
Recursion Pharmaceuticals director Christopher Gibson reported multiple share transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Recursion Pharmaceuticals director Christopher Gibson reported multiple share transactions. He converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold 40,000 Class A shares at $3.46 each under a Rule 10b5-1 trading plan. Separately, 27,265 Class A shares were disposed of to cover tax withholding on restricted stock units.
Insider Trade Summary
Exercise and Sale: 40,000 shares ($138K approx. pre-tax spread)
Exercise and Sale
13 txns
Insider
Gibson Christopher
Role
Director
Sold
40,000 shs ($138K)
Approx. gross sale proceeds
$138K
Approx. exercise cost
$0.00
Approx. pre-tax spread
$138K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 40,000 | $0.00 | $0.00 |
| Conversion | Class A Common Stock | 40,000 | $0.00 | $0.00 |
| Sale | Class A Common Stock | 40,000 | $3.46 | $138K |
| Exercise Price or Tax Liability | Class A Common Stock | 27,265 | $3.49 | $95K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Class B Common Stock — 4,543,334 contracts (Direct);
Class A Common Stock — 906,556 shares (Direct);
Class B Common Stock — 0 contracts (Indirect, by LAHWRAN-3 LLC);
Class B Common Stock — 0 contracts (Indirect, by LAHWRAN-4 LLC);
Class B Common Stock — 0 contracts (Indirect, by Gibson Family Trust);
Stock Option (Right to Buy) — 0 contracts (Direct)
Footnotes (11)
- F1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
- F2. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- F3. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- F4. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- F5. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- F6. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- F7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F8. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F9. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F10. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F11. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Christopher Gibson report at RXRX?
Christopher Gibson reported several transactions involving Recursion Pharmaceuticals (RXRX) stock. He converted 40,000 Class B shares into Class A shares, sold 40,000 Class A shares at $3.46 each, and disposed of 27,265 Class A shares to satisfy tax withholding on restricted stock units.
What does the derivative conversion in the RXRX Form 4 mean?
The Form 4 shows a conversion of 40,000 Class B Common shares into 40,000 Class A Common shares. Each Class B share is convertible into one Class A share at the holder’s option and has no expiration date, as described in the filing footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates